Back to marketplace

Lecture 11

No description yet. This curated deck is ready for daily study.

Total cards: 22•Content version: v4•Public deck•Updated: 8/1/2026

Card preview (22)

#1
Front (Question)

Pharma companies fund their R&D from…..

Back (Answer)

the revenues earned on products successfully introduced into the market and used by patients

#2
Front (Question)

what is the main role of the r&d process

Back (Answer)

add value to the idea

#3
Front (Question)

what is the conceot of attrition and portfolio

Back (Answer)

Multiple projects must be pursued in parallel to ensure product introductions -because the probability is so low that the project will actually succeed

#4
Front (Question)

failures in which phase are the most expensive

Back (Answer)

3

#5
Front (Question)

> 25 project starts -> ….

Back (Answer)

1 product registration

#6
Front (Question)

For more than a decade Pharma have spent billions of dollars on research to find a treatment for Alzheimer’s” ….”……

Back (Answer)

an estimated 150 to 300 experimental Alzheimer’s treatments have failed to show clinical benefits..

#7
Front (Question)

Of 100 failed AD drug programs … …. compounds failed in phase 3

Back (Answer)

30

#8
Front (Question)

Traditional Pharma R&D: programs

Back (Answer)

• Multiple development programs with different risk / reward • Programs with different failure profiles • early (cheap) or late-stage (expensive) failure • Programs of lower innovation • Fast-follower / me-better projects • Incremental innovation

#9
Front (Question)

which therapeutic areas have the highest success rates

Back (Answer)

cardiovascular cns infectuous diseases

#10
Front (Question)

THE TRADITIONAL MODEL: like how the company works

Back (Answer)

• Vertically Integrated Pharma Co. • Large self-sufficient organizations: • Use their own resources for majority of activities - “soup to nuts R&D” • Internal specialist scientists - ideation - project initiation • Associated with high fixed overhead / infrastructure / costs

#11
Front (Question)

The Evolving Pharma R&D model

Back (Answer)

• Focus on “core business”, limit fixed costs, offload routine tasks, access some technologies from specialist service providers • Increased use of service providers, external specialist technologies • Flexibility, short term contracts, reduced costs

#12
Front (Question)

Value / cost of acquisitions is dependent on …..

Back (Answer)

stage of development and product potential

#13
Front (Question)

how do people get money for science

Back (Answer)

-investors pay for the lil things -investors pay using milestone driven investment -exit and IPOs pay money

#14
Front (Question)

what is venture capital

Back (Answer)

-big companies that invest a lot of money in people -VCs raise capital based on their track record of portfolio company successes

#15
Front (Question)

what is domain associate

Back (Answer)

-Founded in 1985 -Raised 2.8 billion $ capital -Started ~260 companies

#16
Front (Question)

PfizerVaccine venture capital

Back (Answer)

-gutenberg uni -biontech -license pfizer

#17
Front (Question)

AstraZeneca Vaccine venture capital

Back (Answer)

-uni of oxford: IP -vaccitech -licence astrazeneca

#18
Front (Question)

j&J vaccine venture capital

Back (Answer)

-beth israel medical center: IP -licencej&j

#19
Front (Question)

moderna vaccine venture capital

Back (Answer)

Founded by: -Flagship Pioneering (VC) -Scientist entrepreneur investors

#20
Front (Question)

Many large pharmaceutical companies now have their own Venture Capital funds that are managed ….

Back (Answer)

and firewalled from the internal research

#21
Front (Question)

JLabs Incubator Labs

Back (Answer)

Currently 81 start-ups in supported; NYC, Boston, Toronto, Washington, LA, San Francisco Also in Belgium, Singapore, Shanghai

#22
Front (Question)

Back (Answer)